Connection

Stephen Kent to Humans

This is a "connection" page, showing publications Stephen Kent has written about Humans.
Connection Strength

0.170
  1. Decay of Fc-dependent antibody functions after mild to moderate COVID-19. Cell Rep Med. 2021 06 15; 2(6):100296.
    View in: PubMed
    Score: 0.008
  2. Hemagglutinin Functionalized Liposomal Vaccines Enhance Germinal Center and Follicular Helper T Cell Immunity. Adv Healthc Mater. 2021 05; 10(10):e2002142.
    View in: PubMed
    Score: 0.007
  3. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021 02 19; 12(1):1162.
    View in: PubMed
    Score: 0.007
  4. Moving the HIV vaccine field forward: concepts of protective immunity. Lancet HIV. 2019 06; 6(6):e406-e410.
    View in: PubMed
    Score: 0.007
  5. Ageing in patients with chronic HIV infection: impact of hypercoagulation. AIDS Res Ther. 2018 11 24; 15(1):22.
    View in: PubMed
    Score: 0.006
  6. Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies. Retrovirology. 2018 08 22; 15(1):58.
    View in: PubMed
    Score: 0.006
  7. Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than neutralization? Curr Opin HIV AIDS. 2018 03; 13(2):160-166.
    View in: PubMed
    Score: 0.006
  8. HIV Reactivation after Partial Protection by Neutralizing Antibodies. Trends Immunol. 2018 05; 39(5):359-366.
    View in: PubMed
    Score: 0.006
  9. Antibody-Dependent Cellular Cytotoxicity Responses to Seasonal Influenza Vaccination in Older Adults. J Infect Dis. 2017 12 27; 217(1):12-23.
    View in: PubMed
    Score: 0.006
  10. A Role for Fc-Mediated Humoral Immunity in Reducing HIV Transmission Rates between HIV Serodiscordant Heterosexual Couples. EBioMedicine. 2017 12; 26:2-3.
    View in: PubMed
    Score: 0.006
  11. Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults. Vaccine. 2017 11 07; 35(47):6451-6458.
    View in: PubMed
    Score: 0.006
  12. Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. Sci Transl Med. 2017 Aug 09; 9(402).
    View in: PubMed
    Score: 0.006
  13. Dimeric Fc? Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of Fc? Receptor Antibodies Induced by the RV144 Vaccine Trial. J Immunol. 2017 07 15; 199(2):816-826.
    View in: PubMed
    Score: 0.006
  14. Expanding role for type I Interferons in restricting HIV growth. Immunol Cell Biol. 2017 05; 95(5):417-418.
    View in: PubMed
    Score: 0.006
  15. Thiol-Reactive Star Polymers Display Enhanced Association with Distinct Human Blood Components. ACS Appl Mater Interfaces. 2017 Apr 12; 9(14):12182-12194.
    View in: PubMed
    Score: 0.006
  16. Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design. Hum Vaccin Immunother. 2017 06 03; 13(6):1-9.
    View in: PubMed
    Score: 0.006
  17. Antibody-dependent cellular cytotoxicity and influenza virus. Curr Opin Virol. 2017 02; 22:89-96.
    View in: PubMed
    Score: 0.006
  18. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight. 2021 08 23; 6(16).
    View in: PubMed
    Score: 0.002
  19. Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein. J Biol Chem. 2021 09; 297(3):101065.
    View in: PubMed
    Score: 0.002
  20. SARS-CoV-2-specific CD8+ T-cell responses and TCR signatures in the context of a prominent HLA-A*24:02 allomorph. Immunol Cell Biol. 2021 10; 99(9):990-1000.
    View in: PubMed
    Score: 0.002
  21. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomater. 2021 09 01; 131:16-40.
    View in: PubMed
    Score: 0.002
  22. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 07; 27(7):1205-1211.
    View in: PubMed
    Score: 0.002
  23. Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences. Eur Respir J. 2021 05; 57(5).
    View in: PubMed
    Score: 0.002
  24. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. Proc Natl Acad Sci U S A. 2021 05 11; 118(19).
    View in: PubMed
    Score: 0.002
  25. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021 06; 21(6):395-404.
    View in: PubMed
    Score: 0.002
  26. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity. 2021 05 11; 54(5):1066-1082.e5.
    View in: PubMed
    Score: 0.002
  27. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat Commun. 2021 04 01; 12(1):2037.
    View in: PubMed
    Score: 0.002
  28. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nat Commun. 2021 03 03; 12(1):1403.
    View in: PubMed
    Score: 0.002
  29. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep Med. 2021 03 16; 2(3):100208.
    View in: PubMed
    Score: 0.002
  30. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nat Rev Immunol. 2020 12; 20(12):727-738.
    View in: PubMed
    Score: 0.002
  31. Suboptimal SARS-CoV-2-specific CD8+ T cell response associated with the prominent HLA-A*02:01 phenotype. Proc Natl Acad Sci U S A. 2020 09 29; 117(39):24384-24391.
    View in: PubMed
    Score: 0.002
  32. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020 10; 5(10):1185-1191.
    View in: PubMed
    Score: 0.002
  33. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020 09; 26(9):1428-1434.
    View in: PubMed
    Score: 0.002
  34. Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of In Vitro versus In Vivo Models. J Virol. 2019 06 01; 93(11).
    View in: PubMed
    Score: 0.002
  35. Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. Front Immunol. 2019; 10:1025.
    View in: PubMed
    Score: 0.002
  36. Immunological basis for enhanced immunity of nanoparticle vaccines. Expert Rev Vaccines. 2019 03; 18(3):269-280.
    View in: PubMed
    Score: 0.002
  37. Minimum information reporting in bio-nano experimental literature. Nat Nanotechnol. 2018 09; 13(9):777-785.
    View in: PubMed
    Score: 0.002
  38. The Multifaceted Nature of Immunoglobulin A and Its Complex Role in HIV. AIDS Res Hum Retroviruses. 2018 09; 34(9):727-738.
    View in: PubMed
    Score: 0.002
  39. The Rare Anaphylaxis-Associated Fc?RIIa3 Exhibits Distinct Characteristics From the Canonical Fc?RIIa1. Front Immunol. 2018; 9:1809.
    View in: PubMed
    Score: 0.002
  40. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nat Commun. 2018 07 10; 9(1):2669.
    View in: PubMed
    Score: 0.002
  41. Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions. J Virol. 2018 06 01; 92(11).
    View in: PubMed
    Score: 0.002
  42. Identification of Native and Posttranslationally Modified HLA-B*57:01-Restricted HIV Envelope Derived Epitopes Using Immunoproteomics. Proteomics. 2018 06; 18(12):e1700253.
    View in: PubMed
    Score: 0.002
  43. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. Lancet HIV. 2018 05; 5(5):e221-e230.
    View in: PubMed
    Score: 0.002
  44. Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC. J Immunol Methods. 2018 06; 457:41-52.
    View in: PubMed
    Score: 0.002
  45. Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. Sci Transl Med. 2018 02 14; 10(428).
    View in: PubMed
    Score: 0.002
  46. 2017 international meeting of the Global Virus Network. Antiviral Res. 2018 05; 153:60-69.
    View in: PubMed
    Score: 0.002
  47. Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission? J Virol. 2017 12 15; 91(24).
    View in: PubMed
    Score: 0.001
  48. Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV. Hum Vaccin Immunother. 2017 11 02; 13(11):2726-2737.
    View in: PubMed
    Score: 0.001
  49. Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. AIDS. 2017 08 24; 31(13):1839-1845.
    View in: PubMed
    Score: 0.001
  50. Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts. J Acquir Immune Defic Syndr. 2017 07 01; 75(3):345-353.
    View in: PubMed
    Score: 0.001
  51. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. J Virol. 2017 05 01; 91(9).
    View in: PubMed
    Score: 0.001
  52. Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection. EBioMedicine. 2017 May; 19:119-127.
    View in: PubMed
    Score: 0.001
  53. Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery. ACS Nano. 2017 01 24; 11(1):54-68.
    View in: PubMed
    Score: 0.001
  54. Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field. Curr HIV Res. 2017; 15(3):202-215.
    View in: PubMed
    Score: 0.001
  55. Recombinant influenza virus expressing HIV-1 p24 capsid protein induces mucosal HIV-specific CD8 T-cell responses. Vaccine. 2016 Feb 24; 34(9):1172-9.
    View in: PubMed
    Score: 0.001
  56. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur J Immunol. 2015 Mar; 45(3):854-64.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.